Laxxon optimises drug delivery thanks to a patented, innovative 3D screen printing process
The technology company Laxxon Medical GmbH is settling in Jena and will in future develop and manufacture innovative medicines here on the basis of a special 3D screen printing process. An additive manufacturing process enables the production of multi-layered pharmaceutical application forms such as tablets. With this technology, tablets can be provided with geometric structures that enable the distribution of one or more active pharmaceutical ingredients. This makes it possible, for example, to achieve a delayed and, above all, consistent release of the active ingredients in the body over a longer period of time. On the one hand, this serves to improve the effectiveness for the benefit of patients, and on the other hand, this patented process offers the pharmaceutical industry completely new product development and manufacturing approaches.
The 3D screen printing process has further advantages: It enables both the production of very small quantities, as required in clinical research, for example, and the mass production of medicines necessary for the pharmaceutical industry. In addition, this special process makes it possible to create a counterfeit-proof “watermark” inside the tablet to protect against counterfeit medicines, something that has been impossible with conventional manufacturing processes. This could be a significant contribution to protection against counterfeit medicines. Counterfeit medicines not only represent a considerable health risk for patients, they also cause annual damage to the pharmaceutical industry in Europe amounting to approximately EUR 10 billion. In summary, it can be said that Laxxon’s 3D screen printing process has considerable potential to quickly achieve high market shares with the help of this innovation. The potential is justified in particular by the fact that in the next 10 years more than 100 drugs with an annual sales volume of USD 150 bn will lose their patent protection worldwide. The interest on the part of the industry to set itself apart from the competition through product improvements is correspondingly high.
bm‑t beteiligungsmanagement thüringen gmbh (bm|t) has joined Laxxon Medical as lead investor through the Thuringian Start-up Fund (TSF) together with other private and institutional investors. Kevin Reeder, Managing Director of bm|t, states: “Laxxon’s decision to choose Jena as the R&D nucleus for their extremely high-potential project confirms the Thuringian university city as an excellent technological location. Laxxon and the 3D screen printing technology will significantly strengthen Jena’s technology and life science cluster.”
The managing directors of Laxxon Medical GmbH, Prof. Dr. A. Schneeberger and K. Kühne, are particularly pleased about the very good and direct cooperation opportunities with the various interdisciplinary institutes of the University of Jena. Their know-how in polymer development and materials research as well as their technical equipment represent a considerable locational advantage for Laxxon, which was also a decisive factor in the company’s decision to settle here.
About Laxxon Medical
Laxxon Medical GmbH, based in Jena, Germany, is a subsidiary of Laxxon Medical AG, domiciled in Zurich (CH), and a sister company of Laxxon Medical Corp., domiciled in New York (USA). Laxxon Medical specialises in the product development and manufacture of pharmaceuticals using the 3D screen printing process. The international pharmaceutical market is to be addressed through these companies.
bm|t, based in Erfurt, is a subsidiary of the Thüringer Aufbaubank and the leading address for investments in Thuringia. The bm|t currently manages eight funds with a total volume of around EUR 320 million, which invest in innovative companies in almost all sectors and in all phases of company development — both in the start-up and growth phases or in company succession situations.